What is Arcturus Therapeutics Holdings Inc.'s (ARCT) StockRank?

MoatMap's StockRank for Arcturus Therapeutics Holdings Inc. (ARCT) is 25/100, with a Sell signal. This is a composite score combining Quality (22), Value (29), and Momentum (61) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Arcturus Therapeutics Holdings Inc. have an economic moat?

Arcturus Therapeutics Holdings Inc. (ARCT) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Arcturus Therapeutics Holdings Inc. a buy, hold, or sell?

MoatMap's current signal for Arcturus Therapeutics Holdings Inc. (ARCT) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Arcturus Therapeutics Holdings Inc. in?

Arcturus Therapeutics Holdings Inc. (ARCT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ARCT

SellHot Air

Arcturus Therapeutics Holdings Inc. · Healthcare · United States · $432M · Avg Vol: $17M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-46.3%

D/E

0.1x

Dividend %

—

COMPANY DESCRIPTION

Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger RNA (mRNA) medicines company focused on the development of infectious disease vaccines and therapies for rare diseases. The company's competitive moat is anchored by its proprietary LUNAR lipid-mediated delivery platform and STARR self-amplifying mRNA technology, which offer potential advantages in dosing and efficacy. It operates as a highly collaborative biotechnology innovator, leveraging strategic partnerships with global pharmaceutical leaders to fund and commercialize its pipeline.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	205.8M	157.7M	138.4M	67.2M	-31.1%	29.4M	18.6M	29.6M	-33.7%
EPS	0.35	-1.00	-3.00	-2.40	—	-3.33	-3.42	-3.61	—
Shares	26.6M	26.8M	27.0M	28.4M	+7.0%	28.4M	—	—	—
Debt	94.8M	30.2M	28.6M	25.0M	-35.9%	22.9M	—	—	—
Equity	270.3M	278.5M	241.0M	214.0M	-7.5%	—	—	—	—
Op CF	32.0M	-18.1M	-59.7M	-74.3M	—	-72.7M	—	—	—
Inv CF	-7.7M	-2.9M	-0.6M	-0.2M	—	—	—	—	—
Fin CF	-2.9M	-24.1M	5.4M	13.4M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+136.1%

SMA 50SMA 200

$13.98

RSI (14)

62.6

52W High

$24.17

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-28.0%25.7

ROE

-46.3%19.6

GP/Assets

-21.2%4.5

Op. Margin

-863.3%7.6

FCF/Assets

n/mN/A

Piotroski

12.4

Int. Cover

-50.0x5.9

D/E Ratio

0.13x58.1

Current Ratio

5.88x76.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-2.8x25.0

P/FCF

n/mN/A

P/B

2.6x52.0

P/S

15.3x19.4

Div Yield

—N/A

Momentum

52W High %

58%36.7

RS 6M

75%95.3

SMA 50/200

1.17x84.3

EPS Rev 4W

+10.2%89.4

EPS Rev 12W

+9.5%85.3

EPS Improve

-8%18.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$432M

P/E (Forward)

-4.4x

Gross Margin

-80.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARCT are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ARCT	Arcturus Therapeutics Holdings Inc.(you)	$432M	25	Sell
XFOR	X4 Pharmaceuticals, Inc.	$401M	25	Sell
BNTC	Benitec Biopharma Inc.	$428M	23	Sell
PRTC.L	PureTech Health plc	$415M	26	Sell
CCCC	C4 Therapeutics, Inc.	$474M	26	Sell
PRLD	Prelude Therapeutics Incorporated	$437M	29	Sell
SABS	SAB Biotherapeutics, Inc.	$345M	25	Sell
RZLT	Rezolute, Inc.	$445M	21	Sell
DNA	Ginkgo Bioworks Holdings, Inc.	$469M	21	Sell
RLMD	Relmada Therapeutics, Inc.	$462M	20	Sell

Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%

Arcturus Therapeutics Holdings Inc. (ARCT): Stock Score Summary

Arcturus Therapeutics Holdings Inc. (ARCT) has a MoatMap StockRank of 25/100 based on Quality (22/100), Value (29/100), and Momentum (61/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$13.98
Market Cap	$432M
P/E (Forward)	-4.38
Price/Book	2.62
Return on Equity	-46.3%
Return on Invested Capital	-28.0%
Debt/Equity	0.13x
Gross Margin	-80.7%
Operating Margin	-863.3%
Revenue Growth	-89.5%
Free Cash Flow	$11M

Arcturus Therapeutics Holdings Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Arcturus Therapeutics Holdings Inc.’s (ARCT) StockRank?: MoatMap’s StockRank for Arcturus Therapeutics Holdings Inc. (ARCT) is 25/100, with a Sell signal. It is a composite of Quality (22), Value (29), and Momentum (61) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Arcturus Therapeutics Holdings Inc. have an economic moat?: Arcturus Therapeutics Holdings Inc. (ARCT) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Arcturus Therapeutics Holdings Inc. a buy, hold, or sell?: MoatMap’s current signal for Arcturus Therapeutics Holdings Inc. (ARCT) is Sell, based on a StockRank of 25/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Arcturus Therapeutics Holdings Inc. in?: Arcturus Therapeutics Holdings Inc. (ARCT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).